Cetuximab Export Market Intelligence: India's 43 Suppliers Shipping to 30 Countries — TransData Nexus 2026

Q: Who are the top cetuximab exporters from India?

The top cetuximab exporters from India are: 1. VAMA LIFECARE PRIVATE LIMITED — $95.8K (11.4% market share); 2. MILES INTERNATIONAL — $51.5K (6.1% market share); 3. MATSUN EXPORTS — $38.8K (4.6% market share); 4. SPR ONCOCARE PRIVATE LIMITED — $37.8K (4.5% market share); 5. NU HOSPITALS PRIVATE LIMITED — $34.5K (4.1% market share). Together they account for 30.8% of India's total cetuximab export value.

Q: What is the total export value of cetuximab from India?

The total export value of cetuximab from India is $839.4K USD, recorded across 115 shipment transactions from 43 active exporters to 30 destination countries. The average shipment value is $7.3K.

Q: Which countries import cetuximab from India?

India exports cetuximab to 30 countries worldwide. The top importing countries are: TURKEY (25.0% share, $210.1K), UNITED KINGDOM (15.6% share, $131.1K), NICARAGUA (15.4% share, $129.6K), SAINT KITTS AND NEVIS (6.0% share, $50.3K), BRAZIL (5.5% share, $46.1K). These five markets account for 67.6% of total export value.

Q: What is the HS code for cetuximab exports from India?

The primary HS code for cetuximab exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of cetuximab exports from India?

The average unit price for cetuximab exports from India is $371.57 USD per unit, with prices ranging from $21.32 to $2750.00 depending on formulation, packaging, and order volume. The total market is valued at $839.4K across 115 shipments.

Q: Which ports handle cetuximab exports from India?

The primary ports for cetuximab exports from India are SAHAR AIR (33.9% of shipments), SAHAR AIR CARGO ACC (INBOM4) (25.2% of shipments), Bombay Air Cargo (10.4% of shipments), BANGALORE ACC (INBLR4) (7.8% of shipments), Bombay Air (7.8% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of cetuximab?

India is one of the world's leading exporters of cetuximab due to its large base of 43 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports cetuximab to 30 countries, demonstrating 15% global market coverage.

Q: What certifications do Indian cetuximab exporters need?

Indian cetuximab exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import cetuximab from India?

There are 51 registered buyers importing cetuximab from India, spread across 30 countries. The repeat buyer rate is 43.1%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top cetuximab supplier from India?

VAMA LIFECARE PRIVATE LIMITED is the leading cetuximab exporter from India with a market share of 11.4% and total export value of $95.8K across 4 shipments. The top 5 suppliers together control 30.8% of total export value.

Suresh Sormare

Cetuximab

India Pharmaceutical Trade Intelligence

$839.4K43 Suppliers30 CountriesHS 30049099

ExportsIndia → TURKEY25.0%India → UNITED KINGDOM15.6%

ImportsGERMANY → India$2.3B BELGIUM → India$121.0K

#1 Supplier: VAMA LIFECARE

Cetuximab Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Cetuximab to the World

Between 2022 and 2026, India exported $839.4K worth of cetuximab across 115 verified shipments to 30 countries — covering 15% of world markets in the Advanced Oncology segment. The largest destination is TURKEY (25.0%). VAMA LIFECARE PRIVATE LIMITED leads with a 11.4% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Cetuximab export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Cetuximab export data snapshot — $839.4K · 43 exporters · 30 countriesTransData Nexus · Indian Customs Data

Top Cetuximab Exporters from India

43 active exporters · Ranked by export value

View all 43 →

Top Cetuximab Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	VAMA LIFECARE PRIVATE LIMITED	$95.8K	4	2	11.4%
2	MILES INTERNATIONAL

Top Countries Importing Cetuximab from India

30 destination markets · Ranked by import value

All 30 countries →

Top Countries Importing Cetuximab from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	TURKEY	$210.1K	25.0%
2	UNITED KINGDOM	$131.1K	15.6%
3	NICARAGUA	$129.6K	15.4%
4	SAINT KITTS AND NEVIS	$50.3K	6.0%
5	BRAZIL	$46.1K	5.5%
6	CAYMAN ISLANDS	$38.9K	4.6%
7	MALDIVES	$34.5K	4.1%
8	KENYA	$33.6K	4.0%
9	UNITED STATES	$24.4K	2.9%
10	JORDAN	$20.6K	2.4%

TURKEY is India's largest cetuximab export destination, absorbing 25.0% of total exports worth $210.1K. The top 5 importing countries — TURKEY, UNITED KINGDOM, NICARAGUA, SAINT KITTS AND NEVIS, BRAZIL — together account for 67.6% of India's total cetuximab export value. The remaining 25 destination countries collectively receive the other 32.4%, indicating a focused distribution strategy targeting key markets.

Who Supplies Cetuximab to India?

6 origin countries · Total import value: $2.3B

India imports cetuximab from 6 countries with a combined import value of $2.3B. The largest supplier is GERMANY ($2.3B, 76 shipments), followed by BELGIUM and FRANCE. All values are from Indian Customs (DGFT) import records.

Countries Supplying Cetuximab to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	GERMANY	$2.3B	76	100.0%
2	BELGIUM	$121.0K	13	0.0%
3	FRANCE	$49.4K	1	0.0%
4	UNITED STATES	$6.6K	13	0.0%
5	UNITED KINGDOM	$3.1K	2	0.0%
6	CHINA	$145	1	0.0%

GERMANY is the largest supplier of cetuximab to India, accounting for 100.0% of total import value. The top 5 origin countries — GERMANY, BELGIUM, FRANCE, UNITED STATES, UNITED KINGDOM — together supply 100.0% of India's cetuximab imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Cetuximab

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

As of March 2026, cetuximab is approved in the United States under the brand name Erbitux, originally approved by the FDA in February 2004. The FDA's Orange Book lists cetuximab as a reference listed drug (RLD), indicating its status as the standard for generic versions. To date, no generic versions of cetuximab have received FDA approval, underscoring the absence of approved Abbreviated New Drug Applications (ANDAs) for this biologic.

The regulatory pathway for biosimilars in the U.S. involves a rigorous evaluation to demonstrate biosimilarity to the reference product. Given the complexity of biologics like cetuximab, the approval process is stringent, contributing to the current lack of approved biosimilar versions. This regulatory environment presents both challenges and opportunities for Indian exporters aiming to enter the U.S. market.

2EU & UK Regulatory Framework

In the European Union, cetuximab is authorized under the brand name Erbitux, with the European Medicines Agency (EMA) granting marketing authorization in June 2004. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has also approved cetuximab for similar indications. Manufacturers exporting cetuximab to these markets must comply with EU Good Manufacturing Practice (GMP) standards, ensuring product quality and safety. Additionally, post-Brexit, the UK has established its own regulatory requirements, necessitating adherence to both EU and UK-specific guidelines for market entry.

3WHO Essential Medicines & Global Standards

As of the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, cetuximab is not included. The WHO's selection criteria focus on medicines that address priority health needs, considering factors such as efficacy, safety, and cost-effectiveness. While cetuximab is recognized for its therapeutic benefits, its exclusion may be attributed to considerations like cost and accessibility in various healthcare settings. Regarding pharmacopoeial standards, cetuximab is included in major compendia such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP), providing standardized quality benchmarks for its production and quality control.

4India Regulatory Classification

In India, cetuximab is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines. As of March 2026, cetuximab is not listed under the DPCO, allowing manufacturers to set prices based on market dynamics. For export purposes, the Central Drugs Standard Control Organization (CDSCO) requires a No Objection Certificate (NOC), ensuring that the exported product meets quality and regulatory standards.

5Patent & Exclusivity Status

Cetuximab's primary patents have expired in major markets, including the U.S. and the EU, opening avenues for biosimilar development. However, the absence of approved biosimilars indicates the challenges associated with replicating complex biologics. The competitive landscape remains limited, with the original manufacturer maintaining a significant market share.

6Recent Industry Developments

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines. The 24th edition, published in September 2025, did not include cetuximab, reflecting ongoing evaluations of its global health impact and accessibility. (who.int)

In January 2026, the WHO emphasized the importance of essential medicines in achieving universal health coverage, highlighting the need for medicines that are effective, safe, and affordable. This underscores the challenges associated with high-cost biologics like cetuximab in resource-limited settings. (who.int)

These developments highlight the dynamic nature of the pharmaceutical regulatory landscape, emphasizing the need for continuous monitoring and adaptation by stakeholders involved in the production and export of cetuximab.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Cetuximab

Retail & reference prices across 9 markets vs. India FOB export price of $371.57/unit

Global Price Benchmark for Cetuximab across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$2,400	USD	Pricing information is based on data from the U.S. Food and Drug Administration (FDA).
United Kingdom	$230	GBP	Pricing information is based on data from the National Health Service (NHS) Drug Tariff.
Germany	$220	EUR	Pricing information is based on data from the Federal Joint Committee (G-BA).
Australia	$210	AUD

Supply Chain Risk Assessment — Cetuximab

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

Cetuximab, a monoclonal antibody used in oncology, relies on complex biotechnological processes for its Active Pharmaceutical Ingredient (API) production. While India has developed capabilities in biopharmaceutical manufacturing, the production of Key Starting Materials (KSMs) and certain intermediates often depends on imports, particularly from China. This dependency is significant, as China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in the sector.

Historical events underscore the risks associated with this reliance. For instance, in 2018, environmental regulatory actions in China led to the shutdown of numerous chemical plants, causing substantial disruptions in the supply of KSMs and intermediates. This resulted in price hikes and supply shortages for various APIs globally. Such incidents highlight the vulnerability of supply chains that are heavily dependent on a single country for critical raw materials.

2Supplier Concentration & Single-Source Risk

Analysis of TransData Nexus's proprietary trade data from 2022 to 2026 reveals that the top five Indian exporters of Cetuximab account for 30.8% of total export value, with VAMA LIFECARE PRIVATE LIMITED leading at an 11.4% share. This indicates a moderate level of supplier concentration. While a diversified exporter base can mitigate risks, the reliance on a few key suppliers still poses potential vulnerabilities, especially if any of these entities face operational challenges.

Access Complete Cetuximab Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 115 transactions across 30 markets.

Request Demo View Pricing

Frequently Asked Questions — Cetuximab Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top cetuximab exporters from India?

The leading cetuximab exporters from India are VAMA LIFECARE PRIVATE LIMITED, MILES INTERNATIONAL, MATSUN EXPORTS, and 5 others. VAMA LIFECARE PRIVATE LIMITED leads with 11.4% market share ($95.8K). The top 5 suppliers together control 30.8% of total export value.

What is the total export value of cetuximab from India?

The total export value of cetuximab from India is $839.4K, recorded across 115 shipments from 43 active exporters to 30 countries. The average shipment value is $7.3K.

Which countries import cetuximab from India?

India exports cetuximab to 30 countries. The top importing countries are TURKEY (25.0%), UNITED KINGDOM (15.6%), NICARAGUA (15.4%), SAINT KITTS AND NEVIS (6.0%), BRAZIL (5.5%), which together account for 67.6% of total export value.

What is the HS code for cetuximab exports from India?

The primary HS code for cetuximab exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Cetuximab

Cetuximab

Top Cetuximab Exporters from India

Top Countries Importing Cetuximab from India

Who Supplies Cetuximab to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Cetuximab

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Cetuximab

Supply Chain Risk Assessment — Cetuximab

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Cetuximab Trade Intelligence

Frequently Asked Questions — Cetuximab Exports from India

Who are the top cetuximab exporters from India?

What is the total export value of cetuximab from India?

Which countries import cetuximab from India?

What is the HS code for cetuximab exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of cetuximab exports from India?

Which ports handle cetuximab exports from India?

Why is India a leading exporter of cetuximab?

What certifications do Indian cetuximab exporters need?

How many buyers import cetuximab from India?

What is the market share of the top cetuximab exporter from India?

Analysis Methodology